Ori Biotech
London, United Kingdom
Platform Provider
Compare CAR-T CDMOs in Europe
Compare CAR-T CDMOs in UK
Compare Cell Therapy CDMOs in Europe
Compare Cell Therapy CDMOs in UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: Ori Biotech
- Signal Score
- 59.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- London, United Kingdom
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Ori Biotech
CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: London, UK
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: London, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals1 articles (not scored)
1 manufacturing site: London, UK
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 1 articles
Company announcements, not verified evidence. They do not change any score.
Ori Biotech’s IRO Platform Earns FDA Advanced Manufacturing Technology Designation - MSN
Ori Biotech’s IRO Platform Earns FDA Advanced Manufacturing Technology Designation MSN
Frequently Asked Questions About Ori Biotech
What is Ori Biotech's CDMO Signal Score?
Ori Biotech has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Ori Biotech for a manufacturing program?
Use the free AI matchmaker to compare Ori Biotech against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Compare Ori Biotech with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.